Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 18/20 | 0.65 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6700976 | 0.83 | MMP13 (0.57) | MMP13SMN1; SMN2 | |
| SCHEMBL6698262 | 0.80 | MMP13 (0.57) | MMP13SLC22A8 | |
| SCHEMBL6302727 | 0.79 | MMP13 (0.75) | MMP13 | |
| SCHEMBL5697007 | 0.79 | MMP13 (1.00) | MMP13SLC22A8 | |
| SCHEMBL6702032 | 0.78 | MMP13 (0.66) | MMP13SLC22A8 | |
| SCHEMBL6699874 | 0.78 | MMP13 (0.65) | MMP13SLC22A8 | |
| SCHEMBL6703229 | 0.77 | MMP13 (0.51) | MMP13SMN1; SMN2 | |
| SCHEMBL6298002 | 0.72 | MMP13 (0.76) | MMP13SLC22A8RECQLMAPK10SMN1; SMN2 | |
| SCHEMBL24754468 | 0.72 | SMN1; SMN2 (0.70) | MMP13RECQLMAPK10SMN1; SMN2 | |
| SCHEMBL6297355 | 0.72 | MMP13 (0.87) | MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | WILSON MICHAEL WILLIAM (US) | 2004-02-26 | — | — | US | disclosed |
| WO-2004014916-A1 | PYRIMIDINE FUSED BICYCLIC METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | MMP9, MMP1, MMP2 | MMP13 13/4885SLC22A8 2959/4885RECQL 1109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.